Xanthurenic Acid Activates mGlu2/3 metabotropic glutamate receptors and is a potential trait marker for schizophrenia

Scientific Reports

Volumn 5, Issue , 2015, Pages

  Fazio, Francesco ^a   Lionetto, Luana ^b   Curto, Martina ^b   Iacovelli, Luisa ^c   Cavallari, Michele ^b,e   Zappulla, Cristina ^a   Ulivieri, Martina ^c   Napoletano, Flavia ^b   Capi, Matilde ^b   Corigliano, Valentina ^b   Scaccianoce, Sergio ^c   Caruso, Alessandra ^c   Miele, Jessica ^c   De Fusco, Antonio ^a   Di Menna, Luisa ^a   Comparelli, Anna ^b   De Carolis, Antonella ^b   Gradini, Roberto ^a,d   Nisticò, Robert ^c,f   De Blasi, Antonio ^g   Girardi, Paolo ^b   Bruno, Valeria ^a,c   Battaglia, Giuseppe ^a   Nicoletti, Ferdinando ^a,c   Simmaco, Maurizio ^b   more..

^a IRCCS NEUROMED   (Italy)

^b SAPIENZA UNIVERSITY OF ROME   (Italy)

^c SAPIENZA UNIVERSITY OF ROME   (Italy)

^d SAPIENZA UNIVERSITY OF ROME   (Italy)

^e BRIGHAM AND WOMEN S HOSPITAL   (United States)

^f IRCCS FONDAZIONE SANTA LUCIA   (Italy)

^g SAPIENZA UNIVERSITY OF ROME   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

BIOLOGICAL MARKER; KYNURENINE; METABOTROPIC RECEPTOR; METABOTROPIC RECEPTOR 2; METABOTROPIC RECEPTOR 3; PROTEIN BINDING; XANTHURENIC ACID;

ADULT; AGED; AGONISTS; ANIMAL; BLOOD; BRAIN; CASE CONTROL STUDY; FEMALE; HEK293 CELL LINE; HUMAN; MALE; METABOLISM; METABOLOMICS; MIDDLE AGED; MOUSE; PROCEDURES; QUANTITATIVE TRAIT; SCHIZOPHRENIA; SIGNAL TRANSDUCTION; SYNAPTIC MEMBRANE; YOUNG ADULT;

ADULT; AGED; ANIMALS; BIOMARKERS; BRAIN; CASE-CONTROL STUDIES; FEMALE; HEK293 CELLS; HUMANS; KYNURENINE; MALE; METABOLOMICS; MICE; MIDDLE AGED; PROTEIN BINDING; QUANTITATIVE TRAIT, HERITABLE; RECEPTORS, METABOTROPIC GLUTAMATE; SCHIZOPHRENIA; SIGNAL TRANSDUCTION; SYNAPTIC MEMBRANES; XANTHURENATES; YOUNG ADULT;

EID: 84949604514     PISSN: None     EISSN: 20452322     Source Type: Journal    
DOI: 10.1038/srep17799     Document Type: Article

References (48)

1. Schwarcz, R., Bruno, J. P., Muchowski, P. J. & Wu, H. Q. Kynurenines in the mammalian brain: when physiology meets pathology. Nat Rev Neurosci. 13, 465-477 (2012).
2. Stone, T. W. & Perkins, M. N. Quinolinic acid: a potent endogenous excitant at amino acid receptors in CNS. Eur J Pharmacol. 72, 411-412 (1981).
3. de Carvalho, L. P., Bochet, P. & Rossier, J. The endogenous agonist quinolinic acid and the non endogenous homoquinolinic acid discriminate between NMDAR2 receptor subunits. Neurochem Int. 28, 445-452 (1996).
4. Parsons, C. G. et al. Novel systemically active antagonists of the glycine site of the N-methyl-D-Aspartate receptor: electrophysiological biochemical and behavioral characterization. J Pharmacol Exp Ther. 283, 1264-1275 (1997).
5. Wonodi, I. et al. Downregulated kynurenine 3-monooxygenase gene expression and enzyme activity in schizophrenia and genetic association with schizophrenia endophenotypes. Arch Gen Psychiatry. 68, 665-674 (2011).
6. Sathyasaikumar, K. V. et al. (2011). Impaired kynurenine pathway metabolism in the prefrontal cortex of individuals with schizophrenia. Schizophr Bull. 37, 1147-1156 (2011).
7. Amori, L., Guidetti, P., Pellicciari, R. & Schwarcz, R. On the relationship between the two branches of the kynurenine pathway in the rat brain in vivo. J Neurochem. 109, 316-325 (2009).
8. Aoyama, N. et al. Association study between kynurenine 3-monooxygenase gene and schizophrenia in the Japanese population. Genes Brain Behav. 5, 364-368 (2006).
9. Moghaddam, B. & Javitt, D. From revolution to evolution: the glutamate hypothesis of schizophrenia and its implication for treatment. Neuropsychopharmacology. 37, 4-15 (2012).
10. Belforte, J. E. et al. Postnatal NMDA receptor ablation in corticolimbic interneurons confers schizophrenia-like phenotypes. Nat Neurosci. 13, 76-83 (2010).
11. Homayoun, H. & Moghaddam, B. NMDA receptor hypofunction produces opposite effects on prefrontal cortex interneurons and pyramidal neurons. J Neurosci. 27, 11496-11500 (2007)
12. Jackson, M. E., Homayoun, H. & Moghaddam, B. NMDA receptor hypofunction produces concomitant firing rate potentiation and burst activity reduction in the prefrontal cortex. Proc Natl Acad Sci USA. 101, 8467-8472 (2004).
13. Sathyasaikumar, K. V., Tararina, M., Wu, H. Q. & Schwarcz, R. Production of xanthurenic acid from 3-hydroxykynurenine in rat and human brain in vitro and in vivo. American Neuroscience Annual Meeting, Abs. 36, 23 (2014).
14. Fazio, F. et al. Cinnabarinic acid, an endogenous metabolite of the kynurenine pathway, activates type 4 metabotropic glutamate receptors. Mol Pharmacol. 81, 643-656 (2012).
15. Copeland, C. S., Neale, S. A. & Salt, T. E. Actions of Xanthurenic acid, a putative endogenous Group II metabotropic glutamate receptor agonist, on sensory transmission in the thalamus. Neuropharmacology. 66, 133-142 (2013).
16. Neale, S. A., Copeland, C. S., Uebele, V. N., Thomson, F. J. & Salt, T. E. Modulation of hippocampal synaptic transmission by the kynurenine pathway member xanthurenic acid and other VGLUT inhibitors. Neuropsychopharmacology. 38, 1060-1067 (2013).
17. González-Maeso, J. et al. Identification of a serotonin/glutamate receptor complex implicated in psychosis. Nature. 452, 93-97 (2008)
18. Marek, G. J., Wright, R. A., Schoepp, D. D., Monn, J. A. & Aghajanian, G. K. Physiological antagonism between 5-hydroxytryptamine (2A) and group II metabotropic glutamate receptors in prefrontal cortex. J Pharmacol Exp Ther. 292, 76-87 (2000).
19. Benassi, C. A., Benassi, P., Allegri, G. & Ballarin, P. Tryptophan metabolism in schizophrenic patients.J Neurochem. 7, 264-270 (1961).
20. Price, J. M., Brown, R. R. & Peter, H. A. Tryptophan metabolism in porphyria, schizophrenia, and a variety of neurologic and psychiatric diseases. Neurology. 9, 456-468 (1959).
21. Schoepp, D. D., Jane, D. E. & Monn, J. A. Pharmacological agents acting at subtypes of metabotropic glutamate receptors. Neuropharmacology. 38, 1431-76 (1999).
22. Schoepp, D. D. et al. The novel metabotropic glutamate receptor agonist 2R,4R-APDC potentiates stimulation of phosphoinositide hydrolysis in the rat hippocampus by 3,5-dihydroxyphenylglycine: evidence for a synergistic interaction between group 1 and group 2 receptors. Neuropharmacology. 35, 1661-1672 (1996).
23. Genazzani, A. A., L'Episcopo, M. R., Casabona, G., Shinozaki, H. & Nicoletti, F. (2S,1? R,2? R,3? R)-2-(2,3-dicarboxycyclopropyl) glycine positively modulates metabotropic glutamate receptors coupled to polyphosphoinositide hydrolysis in rat hippocampal slices. Brain Res. 659, 10-16 (1994).
24. Taleb, O. et al. Xanthurenic acid binds to neuronal G-protein-coupled receptors that secondarily activate cationic channels in the cell line NCB-20. PLoS One. 7, e48553 (2012).
25. Gobaille, S. et al. Xanthurenic acid distribution, transport, accumulation and release in the rat brain. J Neurochem. 105, 982-993 (2008).
26. Bartlett, R. D., Esslinger, C. S., Thompson, C. M. & Bridges, R. J. Substituted quinolones as inhibitors of L-glutamate transport into synaptic vesicles. Neuropharmacology. 37, 839-46 (1998).
27. Carrigan, C. N. et al. 2002. Synthesis and in vitro pharmacology of substituted quinolone-2,4dicarboxylic acids as inhibitors of vesicular glutamate transport. J Med Chem 45, 2260-2276 (2002).
28. Neale, S. A., Copeland, C. S. & Salt, T. E. Effect of VGLUT inhibitors on glutamatergic synaptic transmission in the rodent hippocampus and prefrontal cortex. Neurochem internat 73, 159-165 (2014).
29. Reiter, E., Ahn, S., Shukla, A. K. & Lefkowitz, R. J. Molecular mechanism of ?-Arrestin-biased agonism at seven-transmembrane receptors. Annu Rev Pharmacol Toxicol. 52, 179-197 (2012).
30. Fell, M. J., Svensson, K. A., Johnson, B. G. & Schoepp, D. D. Evidence for the role of metabotropic glutamate (mGlu)2 not mGlu3 receptors in the preclinical antipsychotic pharmacology of the mGlu2/3 receptor agonist (-)-(1R,4S,5S,6S)-4-Amino-2-sulfonylbicyclo[3.1.0]hexane-4,6-dicarboxylic acid (LY404039). J Pharmacol Exp Ther. 326, 209-217 (2008).
31. Woolley, M. L., Pemberton, D. J., Bate, S., Corti, C. & Jones, D. N. The mGlu2 but not the mGlu3 receptor mediates the actions of the mGluR2/3 agonist, LY379268, in mouse models predictive of antipsychotic activity. Psychopharmacology (Berl). 196, 431-440 (2008).
32. Guillemin, G. J. et al. Kynurenine pathway metabolism in human astrocytes: a paradox for neuronal protection. J Neurochem. 78, 842-853 (2001).
33. Heyes, M. P. et al. Human microglia convert l-tryptophan into the neurotoxin quinolinic acid. Biochem J. 320, 595-597 (1996).
34. Giorgini, F. et al. Targeted deletion of kynurenine 3-monooxygenase in mice: a new tool for studying kynurenine pathway metabolism in periphery and brain. J Biol Chem. 288, 36554-36566 (2013).
35. Kegel, M. E. et al. Imbalanced kynurenine pathway in schizophrenia. Int J Tryptophan Res. 16, 15-22 (2014).
36. Linderholm, K. R. et al. Increased levels of kynurenine and kynurenic acid in the CSF of patients with schizophrenia. Schizophr Bull. 38, 426-432 (2012).
37. Erhardt, S. et al. Kynurenic acid levels are elevated in the cerebrospinal fluid of patients with schizophrenia. Neurosci Lett. 313, 96-98 (2001).
38. Moghaddam, B. A mechanistic approach to preventing schizophrenia in at-risk individuals. Neuron. 10, 1-3 (2013).
39. Myint, A. M. et al. Reversal of imbalance between kynurenic acid and 3-hydroxykynurenine by antipsychotics in medicationnaïve and medication-free schizophrenic patients. Brain Behav Immun. 25, 1576-1581 (2011).
40. Condray, R. et al. 3-Hydroxykynurenine and clinical symptoms in first-episode neuroleptic-naive patients with schizophrenia. Int J Neuropsychopharmacol. 14, 756-767 (2011).
41. Yao, J. K. et al. Altered interactions of tryptophan metabolites in first-episode neuroleptic-naive patients with schizophrenia. Mol Psychiatry. 15, 938-953 (2010).
42. Kurita, M. et al. HDAC2 regulates atypical antipsychotic responses through the modulation of mGlu2 promoter activity. Nat Neurosci. 15, 1245-1254 (2012).
43. Iacovelli, L. et al. Regulation of mGlu4 metabotropic glutamate receptor signaling by type-2 G-protein coupled receptor kinase (GRK2). Mol Pharmacol. 65, 103-10 (2004).
44. Iacovelli, L. et al. Regulation of group II metabotropic glutamate receptors by G protein-coupled receptor kinases: mGlu2 receptors are resistant to homologous desensitization. Mol Pharmacol. 75, 991-1003 (2009).
45. Iacovelli, L., Felicioni, M., Nistico, R., Nicoletti, F. & De Blasi, A. Selective regulation of recombinantly expressed mGlu7 metabotropic glutamate receptors by G protein-coupled receptor kinases and arrestins. Neuropharmacology. 77, 303-12 (2014).
46. Aramori, I. et al. Molecular mechanism of desensitization of the chemokine receptor CCR-5: receptor signaling and internalization are dissociable from its role as an HIV-1-co-receptor. EMBO J. 16, 4606-16 (1997).
47. Nicoletti, F. et al. Coupling of inositol phospholipid metabolism with excitatory amino acid recognition sites in rat hippocampus. J Neurochem. 46, 40-46 (1986).
48. Nuechterlein, K. H. et al. The MATRICS Consensus Cognitive Battery, part 1: test selection, reliability, and validity. Am J Psychiatry. 165, 203-213 (2008).